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Abstract
A nonsense variant (p.W358X) of human pancreatic lipase related protein 2 (PNLIPRP2) is
present in different ethnic populations with a high allele frequency. In cell culture experi-
ments, the truncated protein mainly accumulates inside the cells and causes endoplasmic
reticulum stress. Here, we tested the hypothesis that variant p.W358X might increase risk
for chronic pancreatitis through acinar cell stress. We sequenced exon 11 of PNLIPRP2 in a
cohort of 256 subjects with chronic pancreatitis (152 alcoholic and 104 non-alcoholic) and
200 controls of Hungarian origin. We observed no significant difference in the distribution of
the truncation variant between patients and controls. We analyzed mRNA expression in
human pancreatic cDNA samples and found the variant allele markedly reduced. We con-
clude that the p.W358X truncation variant of PNLIPRP2 is expressed poorly and has no sig-
nificant effect on the risk of chronic pancreatitis.
Introduction
Recurrent acute pancreatitis and chronic pancreatitis are inflammatory diseases of the pan-
creas with significant health and economic burdens [1, 2]. After an initial episode of acute pan-
creatitis, 10 to 30% of adults and children have additional episodes and, of those, a large
fraction develop chronic pancreatitis (CP) [3, 4]. Progression of a single episode to chronic
pancreatitis often associates with genetic risk factors in genes encoding digestive enzymes
expressed in pancreatic acinar cells [5–7]. Since the discovery that a genetic variant in PRSS1
(cationic trypsinogen) causes hereditary pancreatitis, most investigations to identify additional
genetic risk factors focused on proteases and their inhibitors [8, 9].
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More recent studies linked genetic variants in pancreatic lipases to increased risk for CP.
The first report described variants in the gene encoding carboxyl ester lipase (CEL) that result
in a form of autosomal dominant CP characterized by early-onset pancreatic insufficiency and
diabetes [10]. A subsequent study found that a hybrid allele resulting from recombination of
CEL and a neighboring pseudogene, CELP, increased risk for CP in northern Europeans [11].
Additionally, a report of two brothers who had a deficiency of pancreatic lipase (PNLIP) and
evidence of CP showed they were homozygous for a missense mutation in PNLIP [12]. Follow-
up studies indicated that the genetic variants of CEL and PNLIP likely cause disease through
increased protein misfolding and maladaptive activation of unfolded protein response path-
ways [11, 13–15]. Importantly, these studies suggest that genetic variants in other pancreatic
lipases, such as the pancreatic lipase related protein 2 (PNLIPRP2), might increase the risk for
CP.
PNLIPRP2 is homologous with PNLIP and both belong to the same large lipase gene family
[16–18]. Unlike PNLIP, which only digests triglycerides, PNLIPRP2 has lipase activity against
triglycerides, phospholipids and galactolipids [16]. In newborn mice, PNLIPRP2 plays a criti-
cal role in fat digestion [19]. Its role in humans remains unclear. Intriguingly, a nonsense vari-
ant (p.W358X) in human PNLIPRP2 is present in different ethnic populations at a high allele
frequency of 0.3 to 0.5 [20]. When expressed in transfected HEK 293T cells, the truncated pro-
tein largely accumulated inside the cells as a detergent-insoluble aggregate and only a small
amount was secreted into the medium [21]. The intracellular aggregates activated the unfolded
protein response. The findings show that p.W358X PNLIPRP2 can alter cellular physiology
through two mechanisms. First, the secretory defect results in a loss of function that might
affect dietary fat digestion. Second, the intracellular aggregates of truncated PNLIPRP2 may
result in a gain of function by placing pancreatic acinar cells at increased risk for injury
through a maladaptive unfolded protein response. In combination with other stressors, the
presence of PNLIPRP2 aggregates could activate cell death and inflammatory pathways leading
to pancreatitis. A similar mechanism was reported for misfolding PRSS1 and carboxypeptidase
A1 (CPA1) mutants, which appear to cause pancreatitis through endoplasmic reticulum stress
[22]. Herein, we investigated whether the p.W358X PNLIPRP2 allele is a genetic risk factor for
CP in patients with alcohol-related and non-alcohol-related CP.
Materials and methods
Nomenclature
Nucleotide numbering follows coding DNA numbering with the first nucleotide of the ATG
translation initiation codon designated as +1. Amino acids are numbered starting with the ini-
tiator methionine of the primary translation product of PNLIPRP2. The NCBI genomic refer-
ence sequence for PNLIPRP2 (NC_000010.11, Homo sapiens chromosome 10, GRCh38.p12
primary assembly) and the NCBI coding DNA reference sequence (NM_005396.4) correspond
to the minor truncation allele. In the present study, we used the major full-length PNLIPRP2
allele as reference for the designation of all PNLIPRP2 variants. In this manner, the nonsense
p.W358X variant becomes the “effect” allele, which is the only biologically meaningful repre-
sentation. Table 1 compares PNLIPRP2 variant designations using the two different reference
sequences and lists the dbSNP numbers for unambiguous identification.
Study subjects
This study used de-identified genomic DNA samples from the registry of the Hungarian Pan-
creatic Study Group (ethical approval number TUKEB 22254-1/2012/EKU; biobanking
approval number IF702-19/2012). Subjects were recruited from 11 Hungarian centers between
PNLIPRP2 truncation variant
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2012 and 2018 and all gave informed consent according to the ethical guidelines of the Decla-
ration of Helsinki. The current study was also approved by the Institutional Review Board at
Boston University (“Analysis of susceptibility genes in patients with chronic pancreatitis”; IRB
number H-35382). A total of 256 unrelated patients with CP, including 152 with alcoholic CP
and 104 with non-alcoholic CP and 200 control subjects with no pancreatic disease were ana-
lyzed. The CP study cohort included patients with a history of recurrent acute pancreatitis
and/or pathological imaging findings consistent with CP, such as pancreatic calcifications,
duct dilatation or irregularities, with or without exocrine pancreatic insufficiency or diabetes.
Patient characteristics are described in Table 2. Alcoholic CP was diagnosed in CP cases with
alcohol consumption of more than 80 g/day (men) or 60 g/day (women) for at least two years.
De-identified pancreatic cDNA and matching genomic DNA samples (n = 9) from cadaveric
donors were obtained from the University of Szeged, Hungary.
DNA sequencing
Primer sequences and amplicon sizes are listed in Table 3. PCR reactions were performed
using 1.0 U HotStar Taq DNA polymerase (Qiagen, Valencia, CA), 0.2 mM dNTP, 2.0 μL 10x
PCR buffer (Qiagen), 0.5 μM primers, and 10–50 ng genomic DNA or cDNA template in a
total volume of 20 μL. Cycling conditions were as follows: 15-min initial heat activation at 95
oC; 40 cycles of 30 s denaturation at 94 oC, 30 s annealing at 60 oC, and 60 s extension at 72 oC;
and final extension for 5 min at 72 oC. Products were verified by 1.5% agarose gel electropho-
resis. PCR amplicons (5 μL) were treated with 1 μL FastAP Thermosensitive Alkaline Phospha-
tase and 0.5 μL Exonuclease I (Thermo Fisher Scientific, Waltham, MA) for 15 min at 37 oC
and the reaction was stopped by heating the samples to 85 oC for 15 min. Sanger sequencing
was performed using the forward PCR primers as sequencing primer. Amplicons containing
the heterozygous c.1070-379delG variant were also sequenced with the reverse primer.
Table 1. Designation of PNLIPRP2 variants with respect to the NCBI reference sequence corresponding to the minor truncation allele and the full-length major
allele used as the reference in this study.
NCBI reference
minor truncation allele
Reference used in this work
major full-length allele
PNLIPRP2
region
dbSNP
number
Nucleotide
change
Amino acid
change
Nucleotide
change
Amino acid
change
Intron 10 c.1070-379delG c.1070-379delG
Intron 10 rs4751994 c.1070-321C>T c.1070-321T>C
Exon 11 rs4751995 c.1074A>G p.X358W c.1074G>A p.W358X
Exon 11 rs4751996 c.1084A>G p.I362V c.1084G>A p.V362I
Exon 11 rs10885997 c.1161A>G p.S387 = c.1161G>A p.S387 =
Intron 11 rs7910135 c.1181+55C>A c.1181+55A>C
The truncation variant is highlighted in bold type.
https://doi.org/10.1371/journal.pone.0206869.t001
Table 2. Study population.
All CP n = 256 NACP n = 104 ACP n = 152 Controls n = 200
Male Female Male Female Male Female Male Female
number 194 62 60 44 134 18 113 87
mean age at recruitment 56±10 56±14 57±12 57±16 55±10 53±9 52±12 52±13
mean age of disease onset 48±12 48±16 47±12 48±18 48±12 48±9 - -
Age values indicate mean ± S.D. in years. CP, chronic pancreatitis, NACP, non-alcoholic chronic pancreatitis, ACP, alcoholic chronic pancreatitis.
https://doi.org/10.1371/journal.pone.0206869.t002
PNLIPRP2 truncation variant
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Results
A common truncation variant in PNLIPRP2
The common truncation variant c.1074G>A (p.W358X) in PNLIPRP2 was first described in 2003
as W357X in European, African and Chinese populations with allele frequencies of 0.53, 0.55 and
0.33, respectively [20]. A 2010 study on the association of common gene variants and human die-
tary habits described the variant as W358X (rs4751995) with similar allele frequencies [23]. The
discrepancy in numbering is because the original cloning study of PNLIPRP2 missed one of the
two consecutive Met codons at the start of the coding sequence [18]. Interestingly, the first Met is
encoded by a separate upstream exon, which should be counted as exon 1 of the PNLIPRP2 gene;
placing the truncation variant in exon 11. The NCBI reference sequence for PNLIPRP2 corre-
sponds to the minor truncation allele. To describe the truncation variant in a biologically mean-
ingful manner, in this study we used the major full-length PNLIPRP2 allele as reference (Table 1).
DNA sequence analysis of exon 11 of human PNLIPRP2
We genotyped 152 subjects with alcoholic CP, 104 subjects with non-alcoholic CP and 200
control subjects, recruited from the registry of the Hungarian Pancreatic Study Group. We
used direct DNA sequencing after PCR amplification of exon 11 and flanking intronic regions
of PNLIPRP2. Within the amplified 793 nt sequence, we found 6 nucleotide variants, which
included three intronic variants (c.1070-379delG, c.1070-321T>C and c.1181+55A>C), one
synonymous variant (c.1161G>A, p.S387 = ), one missense variant (c.1084G>A, p.V362I) and
the truncation variant c.1074G>A (p.W358X) (Fig 1). The commonly occurring variants
c.1070-321T>C, p.W358X, p.V362I, p.S387 = and c.1181+55A>C were found in linkage dis-
equilibrium as a conserved haplotype (CAAAC in Fig 1). Another common haplotype
(CGGAA in Fig 1) was formed by variants c.1070-321T>C and p.S387 = .
When allele frequency was considered, distribution of the variants between patients and
controls showed no significant difference (Table 4). Subgroup analysis for alcoholic and non-
alcoholic CP patients versus controls revealed no association either (Tables 5 and 6). We also
analyzed genotypes using dominant and recessive models but found no significant differences
in genotype frequencies between all CP patients or the alcoholic and non-alcoholic cohorts
versus controls (Tables 7, 8 and 9). Finally, comparison of the three haplotypes between
patients and controls yielded no significant differences with the exception of the CGGAA hap-
lotype (see Fig 1), which was overrepresented in the non-alcoholic CP cohort relative to con-
trols (OR 1.6, P 0.04) (Tables 10, 11 and 12). We consider this a spurious association due to
limited sample size and chance.
Expression of the PNLIPRP2 truncation allele
To estimate the relative mRNA expression of the full-length and truncation alleles of
PNLIPRP2, we used direct sequencing of pancreatic cDNA after PCR amplification of a 732 nt
Table 3. Oligonucleotide primers used for PCR amplification of exon 11 of PNLIPRP2 from genomic DNA (e11 primers) and a portion of the PNLIPRP2 coding
sequence from pancreatic cDNA (RT primers).
Primer name Sequence (5’>3’) Amplicon Annealing
temperature
PNLIPRP2 e11 forward
PNLIPRP2 e11 reverse
GTT CTG GAG GAT GGA AAT CTG
CAA AAG GAG TTA GCA CAT GAC T
836 bp 60 oC
PNLIPRP2 RT forward
PNLIPRP2 RT reverse
CAT CTG GAT TTC TTT CCA AAT GG
CGA GTG CAT TAA AGA TTT TAT TAC CG
732 bp 60 oC
https://doi.org/10.1371/journal.pone.0206869.t003
PNLIPRP2 truncation variant
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fragment of the coding DNA. We obtained nine de-identified cDNA samples with matching
genomic DNA from cadaveric donors. Sequencing of the genomic DNA revealed five hetero-
zygous samples and one sample homozygous for the truncation allele. The electropherograms
of the heterozygous genomic sequences showed two signals at the position of variants p.
W358X and p.V362I, with comparable peak heights (Fig 2A). Surprisingly, when heterozygous
cDNA samples were sequenced, only one peak was visible at these positions, which corre-
sponded to the major full-length allele, whereas no signal was apparent for the minor trunca-
tion allele (Fig 2B). PCR amplification of the pancreatic cDNA sample with the homozygous
truncation allele confirmed the absence of detectable mRNA expression (Fig 2C). Taken
Fig 1. PNLIPRP2 variants in exon 11 and the flanking intronic regions identified in the present study. The truncation variant is in bold type. The three
haplotypes formed by the five commonly occurring variants are also shown.
https://doi.org/10.1371/journal.pone.0206869.g001
Table 4. Allele frequency of PNLIPRP2 variants in patients with chronic pancreatitis (CP) and controls without pancreatic disease.
PNLIPRP2 Nucleotide change Amino acid change CP patient alleles Control alleles OR P value 95% CI
Intron 10 c.1070-379delG 2/512 (0.4%) 1/400 (0.3%) 1.6 0.72 0.14–17.3
Intron 10 c.1070-321T>C 319/512 (62.3%) 240/400 (60%) 1.1 0.48 0.84–1.4
Exon 11 c.1074G>A p.W358X 245/512 (47.9%) 192/400 (48%) 0.99 0.97 0.77–1.3
Exon 11 c.1084G>A p.V362I 245/512 (47.9%) 192/400 (48%) 0.99 0.97 0.77–1.3
Exon 11 c.1161G>A p.S387 = 321/512 (62.7%) 240/400 (60%) 1.1 0.4 0.86–1.5
Intron 11 c.1181+55A>C 246/512 (48%) 192/400 (48%) 1 0.99 0.77–1.3
The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0206869.t004
PNLIPRP2 truncation variant
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together, our observations indicate that the truncation allele is not expressed at the mRNA
level to a significant extent, in all likelihood due to nonsense-mediated mRNA decay.
We also consulted the Genotype-Tissue Expression (GTEx) Portal (www.gtexportal.org/
home) and found that all five common variants within the truncation haplotype were
Table 5. Allele frequency of PNLIPRP2 variants in patients with non-alcoholic chronic pancreatitis (NACP) and controls without pancreatic disease.
PNLIPRP2 Nucleotide change Amino acid change NACP patient alleles Control alleles OR P value 95% CI
Intron 10 c.1070-379delG 1/208 (0.5%) 1/400 (0.3%) 1.9 0.64 0.12–31
Intron 10 c.1070-321T>C 131/208 (63%) 240/400 (60%) 1.1 0.48 0.8–1.6
Exon 11 c.1074G>A p.W358X 93/208 (44.7%) 192/400 (48%) 0.88 0.44 0.63–1.2
Exon 11 c.1084G>A p.V362I 93/208 (44.7%) 192/400 (48%) 0.88 0.44 0.63–1.2
Exon 11 c.1161G>A p.S387 = 131/208 (63%) 240/400 (60%) 1.1 0.48 0.8–1.6
Intron 11 c.1181+55A>C 94/208 (45.2%) 192/400 (48%) 0.89 0.51 0.64–1.3
The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0206869.t005
Table 6. Allele frequency of PNLIPRP2 variants in patients with alcoholic chronic pancreatitis (ACP) and controls without pancreatic disease.
PNLIPRP2 Nucleotide change Amino acid change ACP patient alleles Control alleles OR P value 95% CI
Intron 10 c.1070-379delG 1/304 (0.3%) 1/400 (0.3%) 1.3 0.85 0.08–21.1
Intron 10 c.1070-321T>C 188/304 (61.8%) 240/400 (60%) 1.1 0.62 0.8–1.5
Exon 11 c.1074G>A p.W358X 152/304 (50%) 192/400 (48%) 1.1 0.6 0.8–1.5
Exon 11 c.1084G>A p.V362I 152/304 (50%) 192/400 (48%) 1.1 0.6 0.8–1.5
Exon 11 c.1161G>A p.S387 = 190/304 (62.5%) 240/400 (60%) 1.1 0.5 0.82–1.5
Intron 11 c.1181+55A>C 152/304 (50%) 192/400 (48%) 1.1 0.6 0.8–1.5
The truncation variant is highlighted in bold type. OR, odds ratio; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0206869.t006
Table 7. Genotype distribution of PNLIPRP2 variants in patients with chronic pancreatitis (CP) and in controls.
PNLIPRP2 Nucleotide change Genotype CP patients Controls OR P value 95% CI
Intron 10 c.1070-379delG GG
delG
deldel
254/256 (99.2%)
2/256 (0.8%)
0/256 (0%)
199/200 (99.5%)
1/200 (0.5%)
0/200 (0%)
1.6
0.78
0.72
0.9
0.14–17.4
0.02–39.6
Intron 10 c.1070-321T>C TT
TC
CC
37/256 (14.5%)
119/256 (46.5%)
100/256 (39%)
27/200 (13.5%)
106/200 (53%)
67/200 (33.5%)
0.92
1.3
0.77
0.22
0.54–1.6
0.87–1.9
Exon 11 c.1074G>A GG
GA
AA
68/256 (26.6%)
131/256 (51.2%)
57/256 (22.2%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
0.92
1.1
0.7
0.75
0.6–1.4
0.69–1.7
Exon 11 c.1084G>A GG
GA
AA
68/256 (26.6%)
131/256 (51.2%)
57/256 (22.2%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
0.92
1.1
0.7
0.75
0.6–1.4
0.69–1.7
Exon 11 c.1161G>A GG
GA
AA
37/256 (14.5%)
117/256 (45.7%)
102/256 (39.8%)
27/200 (13.5%)
106/200 (53%)
67/200 (33.5%)
0.92
1.3
0.77
0.16
0.54–1.6
0.89–1.9
Intron 11 c.1181+55A>C AA
AC
CC
68/256 (26.6%)
130/256 (50.8%)
58/256 (22.6%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
0.92
1.1
0.7
0.67
0.6–1.4
0.7–1.7
Data were analyzed assuming dominant (shown in italics) or recessive models of inheritance. The truncation variant is highlighted in bold type. OR, odds ratio; CI,
confidence interval.
https://doi.org/10.1371/journal.pone.0206869.t007
PNLIPRP2 truncation variant
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Table 8. Genotype distribution of PNLIPRP2 variants in patients with non-alcoholic chronic pancreatitis (NACP) and in controls.
PNLIPRP2 Nucleotide change Genotype NACP patients Controls OR P value 95% CI
Intron 10 c.1070-379delG GG
delG
deldel
103/104 (99%)
1/104 (1%)
0/104 (0%)
199/200 (99.5%)
1/200 (0.5%)
0/200 (0%)
1.9
1.9
0.64
0.75
0.12–31.2
0.04–97.4
Intron 10 c.1070-321T>C TT
TC
CC
12/104 (11.5%)
53/104 (51%)
39/104 (37.5%)
27/200 (13.5%)
106/200 (53%)
67/200 (33.5%)
1.2
1.2
0.63
0.49
0.58–2.5
0.73–2
Exon 11 c.1074G>A GG
GA
AA
26/104 (25%)
63/104 (60.6%)
15/104 (14.4%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
1
0.63
1
0.17
0.58–1.7
0.33–1.2
Exon 11 c.1084G>A GG
GA
AA
26/104 (25%)
63/104 (60.6%)
15/104 (14.4%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
1
0.63
1
0.17
0.58–1.7
0.33–1.2
Exon 11 c.1161G>A GG
GA
AA
12/104 (11.5%)
53/104 (51%)
39/104 (37.5%)
27/200 (13.5%)
106/200 (53%)
67/200 (33.5%)
1.2
1.2
0.63
0.49
0.58–2.5
0.73–2
Intron 11 c.1181+55A>C AA
AC
CC
26/104 (25%)
62/104 (59.6%)
16/104 (15.4%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
1
0.68
1
0.24
0.58–1.7
0.36–1.3
Data were analyzed assuming dominant (shown in italics) or recessive models of inheritance. The truncation variant is highlighted in bold type. OR, odds ratio; CI,
confidence interval.
https://doi.org/10.1371/journal.pone.0206869.t008
Table 9. Genotype distribution of PNLIPRP2 variants in patients with alcoholic chronic pancreatitis (ACP) and in controls.
PNLIPRP2 Nucleotide change Genotype ACP patients Controls OR P value 95% CI
Intron 10 c.1070-379delG GG
delG
deldel
151/152 (99.3%)
1/152 (0.7%)
0/152 (0%)
199/200 (99.5%)
1/200 (0.5%)
0/200 (0%)
1.3
1.3
0.85
0.89
0.08–21.2
0.03–66.6
Intron 10 c.1070-321T>C TT
TC
CC
25/152 (16.5%)
66/152 (43.4%)
61/152 (40.1%)
27/200 (13.5%)
106/200 (53%)
67/200 (33.5%)
0.79
1.3
0.44
0.2
0.44–1.4
0.86–2.1
Exon 11 c.1074G>A GG
GA
AA
42/152 (27.6%)
68/152 (44.8%)
42/152 (27.6%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
0.87
1.4
0.58
0.15
0.54–1.4
0.88–2.4
Exon 11 c.1084G>A GG
GA
AA
42/152 (27.6%)
68/152 (44.8%)
42/152 (27.6%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
0.87
1.4
0.58
0.15
0.54–1.4
0.88–2.4
Exon 11 c.1161G>A GG
GA
AA
25/152 (16.5%)
64/152 (42.1%)
63/152 (41.4%)
27/200 (13.5%)
106/200 (53%)
67/200 (33.5%)
0.79
1.4
0.44
0.13
0.44–1.4
0.9–2.2
Intron 11 c.1181+55A>C AA
AC
CC
42/152 (27.6%)
68/152 (44.8%)
42/152 (27.6%)
50/200 (25%)
108/200 (54%)
42/200 (21%)
0.87
1.4
0.58
0.15
0.54–1.4
0.88–2.4
Data were analyzed assuming dominant (shown in italics) or recessive models of inheritance. The truncation variant is highlighted in bold type. OR, odds ratio; CI,
confidence interval.
https://doi.org/10.1371/journal.pone.0206869.t009
Table 10. Distribution of common PNLIPRP2 haplotype alleles in patients with chronic pancreatitis (CP) and in controls.
Haplotype All CP patients Controls OR P value 95% CI
CAAAC 244/512 (47.7%) 191/400 (47.8%) 1 0.98 0.77–1.3
CGGAA 73/512 (14.3%) 48/400 (12.0%) 1.2 0.32 0.83–1.8
TGGGA 191/512 (37.3%) 160/400 (40.0%) 0.89 0.41 0.68–1.2
The truncation haplotype is highlighted in bold type. OR, odds ratio; CI, confidence interval. See Fig 1 for more details.
https://doi.org/10.1371/journal.pone.0206869.t010
PNLIPRP2 truncation variant
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associated with diminished PNLIPRP2 mRNA expression (Fig 3). The GTEx database is an
open-access public resource to study tissue-specific gene expression and its relationship to
genetic variation. The project analyzes global RNA expression within individual human tissues
from deeply genotyped donors and correlates variations in gene expression with genetic
alterations.
Discussion
Physicians have increasingly recognized that CP is a complex disorder associated with multiple
risk factors [24]. For many, particularly children, genetic variants in genes encoding pancreatic
digestive enzymes contribute to the pathophysiology of CP [6]. In this study, we sought to
determine if a common genetic variant in PNLIPRP2 increased the risk for CP. The variant
introduces a premature stop codon, p.W358X, resulting in a truncated protein and in vitro evi-
dence suggests the expressed protein misfolds and activates the unfolded protein response
[21]. We found no correlation of variant p.W358X with CP as a group or sub-grouped into
alcoholic CP or non-alcoholic CP. This finding demonstrates that p.W358X is not a significant
genetic risk factor for CP. We identified additional variants within exon 11 and the flanking
intronic regions of PNLIPRP2, which formed conserved haplotypes. When these haplotypes
were analyzed for disease association, we observed enrichment of the CGGAA haplotype (see
Fig 1) in the non-alcoholic CP cohort. However, statistical significance was barely reached and
we interpret this finding as fortuitous association due to the small sample size.
Because the presumed mechanism whereby variant p.W358X would contribute to CP is by
activating maladaptive unfolded protein response and cell death pathways, we sought to deter-
mine if expression of the p.W358X allele was lower than expression of full length PNLIPRP2. If
so, the levels of truncated protein may not be sufficient to activate the unfolded protein
response. We accomplished this goal in two ways. First, we PCR amplified PNLIPRP2 from
pancreatic cDNA of heterozygous and homozygous p.W358X carriers and analyzed expression
by DNA sequencing and agarose gel electrophoresis. Second, we interrogated the GTEx Portal
database. Both methods confirmed that the amount of mRNA encoding p.W358X PNLIPRP2
is quite low compared to the mRNA amounts for full-length PNLIPRP2. The results suggest
that the mRNA encoding the p.W358X variant undergoes nonsense-mediated decay [25]. In
the previous study that characterized the cellular effects of the p.W358X variant the authors
Table 11. Distribution of common PNLIPRP2 haplotype alleles in patients with non-alcoholic chronic pancreatitis (NACP) and in controls.
Haplotype NACP patients Controls OR P value 95% CI
CAAAC 92/208 (44.2%) 191/400 (47.8%) 0.87 0.41 0.62–1.2
CGGAA 38/208 (18.3%) 48/400 (12.0%) 1.6 0.040� 1.0–2.6
TGGGA 77/208 (37.0%) 160/400 (40.0%) 0.88 0.48 0.62–1.3
The truncation haplotype is highlighted in bold type. OR, odds ratio; CI, confidence interval. See Fig 1 for more details. The asterisk indicates significant association.
https://doi.org/10.1371/journal.pone.0206869.t011
Table 12. Distribution of common PNLIPRP2 haplotype alleles in patients with alcoholic chronic pancreatitis (ACP) and in controls.
Haplotype ACP patients Controls OR P value 95% CI
CAAAC 152/304 (50.0%) 191/400 (47.8%) 1.1 0.55 0.81–1.5
CGGAA 35/304 (11.5%) 48/400 (12.0%) 0.95 0.84 0.60–1.5
TGGGA 114/304 (37.5%) 160/400 (40.0%) 0.90 0.5 0.66–1.2
The truncation haplotype is highlighted in bold type OR, odds ratio; CI, confidence interval. See Fig 1 for more details.
https://doi.org/10.1371/journal.pone.0206869.t012
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used artificial cDNA expression constructs, which lacked introns [21]. Consequently, the
PNLIPRP2 mRNA encoding the truncation variant did not suffer degradation and protein
Fig 2. Expression of the PNLIPRP2 p.W358X truncation variant. A, Electropherogram of the genomic DNA sequence of a
heterozygous carrier showing the double signal at the position of variants p.W358X and p.V362I. B, Electropherogram of the pancreatic
cDNA sequence of the same heterozygous subject. Note the absence of the signal corresponding to the minor truncation allele at the
position of the variants. C, Agarose gel electrophoresis of PCR amplicons from pancreatic cDNA samples of subjects with homozygous A
(minor truncation allele) and G (full-length allele) genotypes. Control reaction was performed with no added template.
https://doi.org/10.1371/journal.pone.0206869.g002
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expression levels achieved were high enough to induce the unfolded protein response. The
present data strongly argue that this cannot be the case when variant p.W358X is expressed
from its native gene in the acinar cells.
Given the low levels of mRNA expression, it is unlikely that p.W358X PNLIPRP2 causes
disease through gain-of-function as suggested by studies in transfected tissue culture cells [21].
In retrospect, it seems reasonable to have predicted that p.W358X PNLIPRP2 should not be a
significant risk factor for CP or another disease since it is so prevalent. More likely, any effect
of p.W358X PNLIPRP2 on human health should result from loss-of-function. Humans harbor
many genetic variants predicted to cause loss-of-function [26]. Homozygosity for loss-of-func-
tion variants either results in a non-fatal phenotype or represent benign variations in redun-
dant genes. A non-fatal loss-of-function phenotype was found in Pnliprp2-deficient mice [19].
Suckling Pnliprp2-deficient mice had fat malabsorption and poor growth but survived to
adulthood and were fertile. It is not known if a similar effect occurs in human infants homozy-
gous for p.W358X PNLIPRP2. In humans, p.W358X PNLIPRP2 may represent a loss-of-func-
tion tolerant genetic variant with the loss of its lipase activity compensated by other lipases
[16]. Alternatively, p.W358X PNLIPRP2 may represent a protective or disease modifying allele
[27]. That is, homozygosity for this allele may confer protection against disease or modify
adaptations to diet [23]. Determination of the importance of the common p.W358X
PNLIPRP2 allele in human health will require additional investigations.
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